333 related articles for article (PubMed ID: 10022397)
1. Serum cytokines in thyrotoxicosis.
Siddiqi A; Monson JP; Wood DF; Besser GM; Burrin JM
J Clin Endocrinol Metab; 1999 Feb; 84(2):435-9. PubMed ID: 10022397
[TBL] [Abstract][Full Text] [Related]
2. Persistent increase in bone turnover in Graves' patients with subclinical hyperthyroidism.
Kumeda Y; Inaba M; Tahara H; Kurioka Y; Ishikawa T; Morii H; Nishizawa Y
J Clin Endocrinol Metab; 2000 Nov; 85(11):4157-61. PubMed ID: 11095447
[TBL] [Abstract][Full Text] [Related]
3. Circulating selectins, intercellular adhesion molecule-1, and vascular cell adhesion molecule-1 in hyperthyroidism.
Wenisch C; Myskiw D; Gessl A; Graninger W
J Clin Endocrinol Metab; 1995 Jul; 80(7):2122-6. PubMed ID: 7541802
[TBL] [Abstract][Full Text] [Related]
4. Bone remodelling markers and serum cytokines in patients with hyperthyroidism.
Akalin A; Colak O; Alatas O; Efe B
Clin Endocrinol (Oxf); 2002 Jul; 57(1):125-9. PubMed ID: 12100080
[TBL] [Abstract][Full Text] [Related]
5. High levels of serum soluble interleukin-2 receptors in hyperthyroid patients: correlation with serum thyroid hormones and independence from the etiology of the hyperthyroidism.
Koukkou E; Panayiotidis P; Alevizou-Terzaki V; Thalassinos N
J Clin Endocrinol Metab; 1991 Oct; 73(4):771-6. PubMed ID: 1909702
[TBL] [Abstract][Full Text] [Related]
6. Serum levels of cytokines in children and adolescents with Graves' disease and non-toxic nodular goiter.
Bossowski A; Urban M
J Pediatr Endocrinol Metab; 2001 Jun; 14(6):741-7. PubMed ID: 11453524
[TBL] [Abstract][Full Text] [Related]
7. Serum levels of the cytokines IL-1beta, IL-6 and ICAM-1 after 131I-treatment of Graves' disease and nodular goiter.
Nygaard B; Jarløv AE; Kristensen LO; Faber J
Horm Metab Res; 2000 Jul; 32(7):283-7. PubMed ID: 10965935
[TBL] [Abstract][Full Text] [Related]
8. Osteoporotic cytokines and bone metabolism on rats with induced hyperthyroidism; changes as a result of reversal to euthyroidism.
Simsek G; Karter Y; Aydin S; Uzun H
Chin J Physiol; 2003 Dec; 46(4):181-6. PubMed ID: 15074839
[TBL] [Abstract][Full Text] [Related]
9. Lack of effect of thyroxine in patients with Graves' hyperthyroidism who are treated with an antithyroid drug.
McIver B; Rae P; Beckett G; Wilkinson E; Gold A; Toft A
N Engl J Med; 1996 Jan; 334(4):220-4. PubMed ID: 8531998
[TBL] [Abstract][Full Text] [Related]
10. Antithyroid drugs as a factor influencing the outcome of radioiodine therapy in Graves' disease and toxic nodular goitre?
Körber C; Schneider P; Körber-Hafner N; Hänscheid H; Reiners C
Eur J Nucl Med; 2001 Sep; 28(9):1360-4. PubMed ID: 11585295
[TBL] [Abstract][Full Text] [Related]
11. Clinical experience with sensitive thyrotropin measurements: diagnostic and therapeutic implications.
Bayer MF; Kriss JP; McDougall IR
J Nucl Med; 1985 Nov; 26(11):1248-56. PubMed ID: 3840528
[TBL] [Abstract][Full Text] [Related]
12. Increase of interferon-gamma-inducible CXC chemokine CXCL10 serum levels in patients with active Graves' disease, and modulation by methimazole therapy.
Antonelli A; Rotondi M; Fallahi P; Romagnani P; Ferrari SM; Barani L; Ferrannini E; Serio M
Clin Endocrinol (Oxf); 2006 Feb; 64(2):189-95. PubMed ID: 16430719
[TBL] [Abstract][Full Text] [Related]
13. An elevation of serum immunoglobulin E provides a new aspect of hyperthyroid Graves' disease.
Yamada T; Sato A; Komiya I; Nishimori T; Ito Y; Terao A; Eto S; Tanaka Y
J Clin Endocrinol Metab; 2000 Aug; 85(8):2775-8. PubMed ID: 10946880
[TBL] [Abstract][Full Text] [Related]
14. Effects of chronic iodine administration on thyroid status in euthyroid subjects previously treated with antithyroid drugs for Graves' hyperthyroidism.
Roti E; Gardini E; Minelli R; Bianconi L; Salvi M; Gavaruzzi G; Braverman LE
J Clin Endocrinol Metab; 1993 Apr; 76(4):928-32. PubMed ID: 7682562
[TBL] [Abstract][Full Text] [Related]
15. E-selectin, L-selectin, ICAM-1 and IL-6 concentrations changes in the serum of patients with hyperthyroidism in the early period of radioiodine I-131 therapy.
Jurgilewicz DH; Rogowski F; Łebkowska U; Citko A; Jaroszewicz E; Parfieńczyk A
Nucl Med Rev Cent East Eur; 2002; 5(1):39-42. PubMed ID: 14600946
[TBL] [Abstract][Full Text] [Related]
16. Increased serum CXCL10 in Graves' disease or autoimmune thyroiditis is not associated with hyper- or hypothyroidism per se, but is specifically sustained by the autoimmune, inflammatory process.
Antonelli A; Fallahi P; Rotondi M; Ferrari SM; Romagnani P; Grosso M; Ferrannini E; Serio M
Eur J Endocrinol; 2006 May; 154(5):651-8. PubMed ID: 16645011
[TBL] [Abstract][Full Text] [Related]
17. High serum osteoprotegerin levels in patients with hyperthyroidism: effect of medical treatment.
Amato G; Mazziotti G; Sorvillo F; Piscopo M; Lalli E; Biondi B; Iorio S; Molinari A; Giustina A; Carella C
Bone; 2004 Sep; 35(3):785-91. PubMed ID: 15336617
[TBL] [Abstract][Full Text] [Related]
18. Serum ratio of triiodothyronine to thyroxine, and thyroxine-binding globulin and calcitonin concentrations in Graves' disease and destruction-induced thyrotoxicosis.
Amino N; Yabu Y; Miki T; Morimoto S; Kumahara Y; Mori H; Iwatani Y; Nishi K; Nakatani K; Miyai K
J Clin Endocrinol Metab; 1981 Jul; 53(1):113-6. PubMed ID: 6165731
[TBL] [Abstract][Full Text] [Related]
19. Serum interleukin-6 in amiodarone-induced thyrotoxicosis.
Bartalena L; Grasso L; Brogioni S; Aghini-Lombardi F; Braverman LE; Martino E
J Clin Endocrinol Metab; 1994 Feb; 78(2):423-7. PubMed ID: 8106631
[TBL] [Abstract][Full Text] [Related]
20. Dissociation of responsiveness to thyrotropin-releasing hormone and thyroid suppressibility following antithyroid drug therapy of hyperthyroidism.
Martino E; Pinchera A; Capiferri R; Macchia E; Sardano G; Bartalena L; Mazzanti F; Baschieri L
J Clin Endocrinol Metab; 1976 Sep; 43(3):543-9. PubMed ID: 821960
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
